Security key
363225202
GALECTIN THERAPEUTICS INC - COMMON STOCK (GALT)
CUSIP: 363225202
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 40,603
- Total 13F value
- $153,420
- Share change
- +622
- SEC-reported price per share
- $3.88
- Number of holders
- 9
- Value change
- +$2,140
- Number of buys
- 4
- Number of sells
- 1
- Shares outstanding
- 110,899,890
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
9
Top holders
9
GALT full security history
Ownership snapshot
Full 13F holder table
GALECTIN THERAPEUTICS INC SEC filings
GALECTIN THERAPEUTICS INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 363225202
Recent filing periods:
Ownership snapshot
Top reported holders of GALT - GALECTIN THERAPEUTICS INC - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Richard E. Uihlein
Disclosed value leader
Richard E. Uihlein
Comparable rows
1/15
Latest evidence
31 Jul 2026
13D/G
3/4/5
13F
Lead comparable stake: 49%
14 rows are not safely comparable across share classes.
13D/G row: Richard E. Uihlein
Showing 1-6 of 15 holder rows.
Quick read
Richard E. Uihlein leads the comparable SEC ownership view at 49%.
1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Richard E. Uihlein's linked filing trail.
Comparable ownership
Top 1
Richard E. Uihlein
49%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Richard E. Uihlein |
13D/G
3/4/5
Director, 10%+ Owner
|
49%
Reported 13D/G
· 31 Jul 2026
|
$251,498,772
54,673,646 shares
|
$0 | 31 Jul 2026 |
| 10X Fund, L.P. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$37,392,283
5,614,457 shares
|
-$1,581,991 | 02 Dec 2025 |
| James C. Czirr |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$1,160,550
1,045,541 shares
|
— | 03 Feb 2025 |
| BlackRock, Inc. |
13F
Company
|
—
denominator unverified
|
$13,865,957
2,988,353 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$10,059,822
2,168,065 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
denominator unverified
|
$6,072,509
1,308,394 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
9
Shares
40,603
Rows available
9
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
98
Q3 2026 holders
9
Holder diff
-89
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend